Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India and internationally. The company offers discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and discovery analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also provides development services in biologics; and carries out exploratory/discovery, In Vitro and Genetic toxicology, and developmental and reproductive, as well as acute, sub-chronic, and chronic toxicity studies. In addition, the company offers chemical and formulation development, polymer research, and analytical services. Further, it provides target identification and validation, lead generation and optimization, lead selection, preclinical development, API, and drug product development services. Additionally, the company offers clinical trial management, PK analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. It also provides bioinformatics research, antibody drug conjugate discovery and development, and oligonucleotide synthesis services. The company serves start-up companies, pharma/biotech, agrochemical, chemical, nutrition, and animal health companies. It has partnerships with Bristol-Myers Squibb Co.; Baxter International Inc.; Amgen Inc.; Zoetis Inc.; GSK; Merck KGaA; Artelo Biosciences, Inc.; PharmAust Limited; HiMedia Laboratories; and Zumutor Biologics. The company was incorporated in 1993 and is based in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited. The ISIN of this stock is INE398R01022.